
    
      The present clinical trial aims to investigate and provide a more precise characterization of
      the pharmacokinetic and pharmacodynamic profile of MTR107 in a population of ESRD patients
      predisposed to developing intradialytic hypotension. The study is also designed as a dose
      esclating study aiming to assess MTR107 safety.
    
  